SERES THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5599 USD | -4.16% |
|
-14.48% | -60.01% |
| Apr. 09 | Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT | CI |
| Apr. 08 | Declaration of Voting Results by Seres Therapeutics | CI |
Financials (USD)
| Sales 2024 * | 1.16M | Sales 2025 * | 7.64M | Capitalization | 84.55M |
|---|---|---|---|---|---|
| Net income 2024 * | -186M | Net income 2025 * | -153M | EV / Sales 2024 * | 216 x |
| Net Debt 2024 * | 167M | Net Debt 2025 * | 243M | EV / Sales 2025 * | 42.9 x |
| P/E ratio 2024 * |
-0.49
x | P/E ratio 2025 * |
-0.7
x | Employees | 233 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Seres Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -4.16% | ||
| 1 week | -14.48% | ||
| Current month | -27.67% | ||
| 1 month | -30.57% | ||
| 3 months | -54.48% | ||
| 6 months | -57.10% | ||
| Current year | -60.01% |
1 week
0.54
0.66
1 month
0.540.84
Current year
0.542.05
1 year
0.546.73
3 years
0.5425.06
5 years
0.5438.50
10 years
0.5452.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eric Shaff
CEO | Chief Executive Officer | 48 | 14-10-31 |
David Ege
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-10-21 |
| Chief Tech/Sci/R&D Officer | - | 15-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 78 | 15-03-31 |
| Director/Board Member | 68 | 23-01-03 | |
Richard Kender
BRD | Director/Board Member | 68 | 14-10-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.06% | 0 M€ | 0.00% | - | |
| 0.06% | 2 M€ | -.--% | ||
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 237 M€ | +0.46% | - | |
| 0.02% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.5599 | -4.16% | 3,748,612 |
| 24-04-18 | 0.5842 | -6.87% | 3,788,552 |
| 24-04-17 | 0.6273 | -1.38% | 4,825,050 |
| 24-04-16 | 0.6361 | +2.95% | 4,161,240 |
| 24-04-15 | 0.6179 | -5.62% | 3,852,426 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.5599
USD
Average target price
7.22
USD
Spread / Average Target
+1,189.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.01% | 84.55M | |
| -3.10% | 102B | |
| +2.11% | 96.37B | |
| -1.80% | 21.37B | |
| -17.75% | 20.92B | |
| -6.91% | 18.64B | |
| -42.00% | 16.4B | |
| -28.19% | 13.53B | |
| +0.18% | 13.28B | |
| +19.90% | 10.85B |
- Stock Market
- Equities
- MCRB Stock
